Skip to main content

Market Overview

Abbott Labs To Launch Point-Of-Care Test That Can Detect Coronavirus Within 5 Minutes

Abbott Labs To Launch Point-Of-Care Test That Can Detect Coronavirus Within 5 Minutes

The FDA has approved a potential game-changing test for the novel coronavirus (COVID-19).

Late Friday, Abbott Laboratories (NYSE: ABT) announced the U.S. Food and Drug Administration issued Emergency Use Authorization for the fastest available molecular point-of-care test for the detection of novel coronavirus, which can deliver positive results in as little as five minutes and negative results in 13 minutes.

Benzinga is covering every angle of how the coronavirus affects the financial world. For daily updates, sign up for our coronavirus newsletter.

"The COVID-19 pandemic will be fought on multiple fronts, and a portable molecular test that offers results in minutes adds to the broad range of diagnostic solutions needed to combat this virus," said Robert B. Ford, Abbott's president and chief operating officer. "With rapid testing on ID NOW, healthcare providers can perform molecular point-of-care testing outside the traditional four walls of a hospital in outbreak hotspots."

Abbott will make ID NOW COVID-19 tests available next week to health care providers in urgent care settings in the U.S., where the majority of ID NOW instruments are in use today.

Abbott's stock closed Friday's session at $74.56 per share.

Related Links:

How The Coronavirus Is Impacting Everyday Lives

Markets End Historically Volatile Week On Uneven Note


Related Articles (ABT)

View Comments and Join the Discussion!

Posted-In: coivd-19 CoronavirusNews Health Care General Best of Benzinga

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at